Allergy Immunotherapy Market Report and Forecast 2024-2032

The global allergy immunotherapies market size was valued at USD 2.2 billion in 2023. It is expected to grow at a CAGR of 9.60% during the forecast period of 2024-2032, driven by the increasing innovations in the formulation and delivery of allergen immunotherapy (AIT). The market is experiencing robust growth and is expected to reach USD 5.1 billion by 2032.

Global Allergy Immunotherapies Market Analysis

Allergy immunotherapies, also known as allergy shots or subcutaneous immunotherapies (SCIT), are a significant sector in the treatment of allergic disorders. This treatment involves gradually increasing doses of allergens to build tolerance and reduce symptoms.

Market Drivers

• Growing Prevalence of Allergic Disorders: There is a rising global prevalence of allergies such as rhinitis, asthma, and food allergies. This increase drives demand for effective long-term treatment options, boosting the allergy immunotherapy market.
• Advancements in Allergen Immunotherapy (AIT): Innovations in the formulation and delivery of AIT, including sublingual immunotherapies (SLIT) and the development of recombinant allergens, are making treatments more effective and convenient, thereby attracting more patients.
• Increased Awareness and Diagnosis: Enhanced awareness about allergic diseases and their impact, coupled with improved diagnostic techniques, is encouraging more individuals to seek definitive treatments like immunotherapies.
• Supportive Regulatory Environment: Regulatory approvals for new immunotherapy treatments and streamlined pathways for their approval are positively influencing market growth. For example, the approval of products like Odactra for house dust mite allergies represents significant progress.

Market Challenges

• High Cost of Treatment: Allergy immunotherapy can be expensive, particularly when long treatment durations are required. This can be a significant barrier, especially in regions without adequate healthcare coverage or insurance.
• Availability and Accessibility Issues: In many parts of the world, especially in developing regions, access to specialised allergen immunotherapy is limited. This restricts market growth and patient access to these therapies.
• Side Effects and Safety Concerns: Although generally safe, allergy immunotherapy can have side effects ranging from mild local reactions to severe systemic reactions. These safety concerns can deter some patients from opting for this treatment.
• Competition from Alternative Treatments: Over-the-counter antihistamines and corticosteroids often provide quicker symptom relief at a lower cost, which can make them more appealing to patients than the long-term commitment of immunotherapy.

Future Opportunities

• Technological Innovations: Emerging technologies that improve the safety and efficacy of immunotherapies, such as peptide-based therapies which reduce the risk of severe reactions, are expected to drive market growth.
• Expansion in Emerging Markets: Increasing healthcare spending and infrastructure improvements in emerging markets present significant opportunities for the expansion of allergy immunotherapy.
• Personalised Medicine: The trend towards personalised medicine can be leveraged in allergy immunotherapy to develop customised treatments that are tailored to individual allergic profiles, improving outcomes and patient satisfaction.
• Integration with Digital Health Tools: Utilising digital health tools for better patient management and adherence monitoring can enhance the effectiveness of treatment regimes and patient experience.

Global Allergy Immunotherapies Market Trends

The market for allergy immunotherapies is an evolving landscape, shaped by rising allergy prevalence, technological advancements, and shifting healthcare policies. Here are some insightful market trends in this sector:

Growing Prevalence of Allergic Conditions: Increasing urbanisation, changes in lifestyle and dietary habits, and higher pollution levels are contributing to a rise in allergic diseases globally. This increase in allergy prevalence is driving demand for effective long-term treatment solutions, such as allergy immunotherapies.

• Technological Advancements in Treatment Modalities: There has been significant progress in the development of sublingual immunotherapies (SLIT) and other non-invasive delivery methods. These technologies improve patient compliance and comfort by offering alternatives to traditional subcutaneous immunotherapies (SCIT), which involve injections.
• Expansion of Allergen Coverage: Research and development efforts are expanding to include a wider range of allergens in immunotherapy treatments, including tree nuts, shellfish, and various types of pollens. This expansion aims to provide tailored and more effective solutions to a broader patient base.
• Personalised Medicine and Biomarkers: The trend towards personalised medicine is influencing the allergy immunotherapy sector. There is a growing focus on identifying biomarkers that can predict individual responses to immunotherapy, which could lead to more customised and effective treatment plans.
• Regulatory Support and Product Approvals: Regulatory agencies in various regions are recognising the importance of allergy immunotherapies. There has been an increase in the approval of new therapies and products, which is encouraging investment and innovation in the field.
• Rising Awareness and Education: Governments and health organisations are increasing efforts to raise awareness about the effectiveness of immunotherapies in managing allergies. This educational push is expected to increase the uptake of these treatments among patients who were previously reliant on symptomatic medications.
• Partnerships and Collaborations: Companies in the allergy immunotherapy space are increasingly entering into partnerships and collaborations to leverage each other’s strengths in terms of technology, marketing, and geographic reach. This trend is helping to accelerate the development and distribution of new therapies globally.
• Challenges in Market Access and Reimbursement: Despite the advancements and benefits of allergy immunotherapies, issues related to market access and reimbursement continue to pose challenges. Varying reimbursement policies across countries and the high cost of long-term treatment can limit patient access to these therapies.

Global Allergy Immunotherapies Market Segmentation

Market Breakup by Type of Immunotherapy

• Subcutaneous Immunotherapy (SCIT)
• Sublingual Immunotherapy (SLIT)

The allergy immunotherapy market is segmented into Subcutaneous Immunotherapy (SCIT) and Sublingual Immunotherapy (SLIT). SCIT, the traditional form, continues to drive substantial market share due to its established efficacy, but faces limitations due to the need for frequent clinic visits. SLIT, on the other hand, is rapidly gaining traction due to its non-invasive nature and ease of administration, enhancing patient compliance. Market growth is propelled by increasing allergy prevalence, demand for patient-friendly treatment modalities, and technological advancements in allergen formulations. SLIT, in particular, is poised to drive market growth in the forecast period, as it offers significant advantages in terms of convenience and potential for home-based treatment, aligning with global trends towards telemedicine and patient-centered care.

Market Breakup by Allergy Type

• Allergic Rhinitis
• Asthma
• Food Allergy
• Venom Allergy
• Others

The allergy immunotherapy market is categorised by allergy type, including Allergic Rhinitis, Asthma, Food Allergy, Venom Allergy, and Others. Allergic Rhinitis is a major segment, driven by its high prevalence globally and the availability of effective immunotherapy options. Asthma-related immunotherapies are also significant, given the critical need for long-term treatment solutions. Food and Venom allergies are rapidly emerging segments due to rising awareness and the development of targeted treatments. The market is driven by the increasing global incidence of allergies, advancements in specific immunotherapies, and growing patient awareness and healthcare spending. Looking forward, the segments addressing severe and life-threatening allergies, such as food and venom allergies, are expected to witness robust growth, fueled by urgent medical needs and significant investment in research and development. This diverse demand across various allergy types is poised to collectively drive substantial market growth during the forecast period.

Market Breakup by Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

The allergy immunotherapy market is segmented by distribution channels into Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy. Hospital Pharmacies hold a significant share due to their direct linkage with treatment centers and patient trust in hospital-prescribed therapies. Retail Pharmacies are crucial for accessibility, offering widespread availability of immunotherapies across diverse locations. Online Pharmacies are rapidly growing, fueled by the convenience of home delivery and the increasing digitisation of healthcare services. Market drivers include the rising prevalence of allergies, the convenience of online medicine procurement, and the expansion of healthcare infrastructure. Future growth is especially promising for Online Pharmacies, as e-health services expand and consumer preferences shift towards digital platforms, positioning this segment to significantly drive market growth in the coming years.

Market Breakup by Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

The allergy immunotherapy market is segmented by region into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America dominates the market, driven by high healthcare spending, advanced medical infrastructure, and a large patient population with allergies. Europe follows closely, supported by strong regulatory frameworks and widespread adoption of both SCIT and SLIT. Asia Pacific is the fastest-growing region, due to rising awareness of allergy treatments, increasing healthcare investments, and a growing middle class. Latin America and the Middle East and Africa are emerging markets, where growth is spurred by improving healthcare systems and increasing access to medical treatments. Overall, the global expansion of the allergy immunotherapy market is fueled by increasing global allergy prevalence, technological advancements in treatment, and a growing emphasis on effective long-term care, with Asia Pacific expected to exhibit the highest growth rate in the forecast period due to rapid healthcare evolution and demographic changes.

Global Allergy Immunotherapies Market Competitive Landscape

The competitive landscape of the allergy immunotherapy market is characterised by the presence of several key players who are actively engaging in various strategic activities to enhance their market position. Leading companies include ALK-Abello A/S, Allergy Therapeutics, Stallergenes Greer, HAL Allergy Holding B.V., DBV Technologies, Merck KGaA, Aimmune Therapeutics, NIOX, Anergis S.A., and Allergopharma GmbH & Co. KG. These market participants frequently undertake mergers and acquisitions to expand their geographical reach and product portfolio. Research and development initiatives are common as companies strive to innovate and improve the efficacy and safety of their immunotherapy solutions. New product introductions are regularly made to cater to a broader range of allergies. Additionally, partnerships are formed to leverage collective technological, clinical, and commercial expertise, thereby enhancing the development and distribution of advanced immunotherapeutic products. These activities collectively contribute to a dynamic and competitive market environment.

Key Questions Answered in the Report

• What is the current and future performance of the global allergy immunotherapies drugs market?
• What are the main challenges facing the global allergy immunotherapies drugs market?
• What are the key drivers of the global allergy immunotherapies drugs market?
• What emerging trends are shaping the future of the allergy immunotherapies drugs market?
• How is urbanisation influencing the demand for allergy immunotherapies globally?
• Why do emerging markets present significant opportunities for the expansion of allergy immunotherapy?
• Why is there an increasing demand for allergy immunotherapies globally?
• How are biomarkers transforming the customisation of allergy immunotherapy treatments?
• How are online pharmacies impacting the accessibility of allergy immunotherapies?
• What strategic activities are key players in the allergy immunotherapy market undertaking?

Key Benefits for Stakeholders

• The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the global allergy immunotherapies market from 2017-2032.
• The research report provides the latest information on the market drivers, challenges, and opportunities in the allergy immunotherapies market.
• The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
• Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the allergy immunotherapies industry and its attractiveness.
• The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.

This product will be delivered within 5-7 business days.